CPT2 disease, formally called carnitine palmitoyltransferase II deficiency, is a rare genetic disorder that prevents your body from properly converting fat into energy. It affects an estimated 1 to 9 people per 100,000 and ranges in severity from a mild, muscle-focused form that appears in adolescence to a life-threatening condition that presents at birth.
How the Body Normally Burns Fat for Energy
Your cells burn fat for fuel inside structures called mitochondria. But long-chain fatty acids, the most common type of fat your body uses, can’t pass through the mitochondrial walls on their own. They need a shuttle system to get inside.
The process works in steps. First, a fatty acid links to a helper molecule in the cell’s fluid. Then an enzyme called CPT1, sitting on the outer membrane of the mitochondria, attaches the fatty acid to a carrier molecule called carnitine. This carnitine package crosses to the inner membrane, where a second enzyme, CPT2, strips off the carnitine and converts the fatty acid back into a form the mitochondria can burn for energy.
In CPT2 disease, that second enzyme is missing or doesn’t work properly. The fatty acids get stuck at the inner membrane, and the mitochondria can’t complete the job. This means your body struggles to produce energy from fat, which becomes a serious problem during situations that increase your body’s demand for fat-burning: prolonged exercise, fasting, illness, or cold exposure.
Three Forms With Very Different Severity
CPT2 deficiency comes in three distinct forms, and the differences between them are dramatic.
Lethal Neonatal Form
The most severe form appears within days of birth. Affected infants develop liver failure, respiratory distress, a weakened heart muscle, and irregular heartbeat. The brain and kidneys are often structurally abnormal, with changes including cystic kidney disease and disrupted brain development. Blood sugar drops dangerously low while the body fails to produce ketones, an alternative fuel source. Death typically occurs within days to months.
Severe Infantile Form
This form affects the liver, heart, and muscles, with symptoms usually appearing within the first year of life. Children experience recurring episodes of dangerously low blood sugar, seizures, liver problems, heart muscle weakness, and limb weakness. Episodes can be triggered by fasting or common childhood illnesses like viral infections. Cardiac rhythm problems can cause sudden death during infancy.
Myopathic Form
The myopathic form is by far the mildest and most common type. It primarily affects skeletal muscle, causing recurring episodes of muscle pain and weakness. The first episode typically occurs during childhood or adolescence, though onset has been reported anywhere from the first to the sixth decade of life. Between episodes, people generally feel normal and show no signs of muscle disease.
The hallmark of this form is rhabdomyolysis, a condition where muscle tissue breaks down and releases a protein called myoglobin into the bloodstream. This can turn urine red or brown, which is often the symptom that prompts someone to seek medical attention.
What Triggers an Episode
In the myopathic form, episodes of muscle breakdown don’t happen randomly. They follow a pattern tied to situations where the body leans heavily on fat for fuel. The most common triggers include:
- Prolonged exercise, particularly when combined with skipping meals
- Fasting or going extended periods without eating
- Cold exposure, which forces the body to burn more fuel to maintain temperature
- Infections and fever, which ramp up the body’s energy demands
- Emotional or physical stress
Many people learn their triggers over time and can reduce episodes by adjusting their habits. But when an episode does occur, the consequences can be serious.
Kidney Failure: The Main Acute Risk
When muscle tissue breaks down in large amounts, the released myoglobin can clog and damage the kidneys. A systematic review of CPT2-related rhabdomyolysis cases found that 84% of patients who needed acute care developed kidney failure as the primary complication. About 61% of hospitalized patients required some form of kidney support to get through the crisis.
The good news: outcomes after these acute episodes are generally very good. Most people recover kidney function fully once the episode resolves. But the severity of the kidney injury during an episode means that dark or discolored urine after a known trigger warrants urgent medical attention.
How CPT2 Disease Is Inherited
CPT2 deficiency follows an autosomal recessive inheritance pattern. This means a child must inherit a faulty copy of the CPT2 gene from both parents to develop the disease. Parents who each carry one faulty copy typically have no symptoms themselves. With each pregnancy, two carrier parents have a 25% chance of having an affected child.
Diagnosis and Newborn Screening
The condition can be detected through a blood test that measures specific fat-metabolism markers called acylcarnitines. In CPT2 deficiency, long-chain acylcarnitines (particularly C16 and C18:1) are elevated. The ratio of these long-chain markers to a short-chain marker called C2 is a key diagnostic signal.
Newborn screening can catch the severe forms early. In the United States, CPT2 deficiency is listed as a secondary condition on the Recommended Uniform Screening Panel, meaning it may be detected as part of screening for related conditions. Some programs screen for it directly. The screening uses a blood sample collected from a heel prick within 24 to 48 hours of birth, analyzed with a technology called tandem mass spectrometry. One limitation: the screening can’t distinguish between CPT2 deficiency and a closely related condition called CACT deficiency, so additional testing is needed to confirm the diagnosis.
For the myopathic form, diagnosis often comes later, sometimes after a person has already experienced one or more unexplained episodes of muscle pain and dark urine. Genetic testing can confirm the specific mutations in the CPT2 gene.
Managing the Condition
There is no cure for CPT2 deficiency, so management focuses on preventing episodes and minimizing their severity. The approach differs depending on the form.
For the myopathic form, the standard strategy involves reducing long-chain fat in the diet and increasing carbohydrate intake. The logic is straightforward: if your body can’t burn long-chain fats well, give it more of what it can burn (carbohydrates and medium-chain fats) and less of what it can’t. Medium-chain triglyceride (MCT) oil is sometimes used as a supplement because medium-chain fats can enter the mitochondria without the CPT2 enzyme.
Results with conventional dietary approaches have been mixed. Traditional low-fat, high-carbohydrate diets with MCT supplementation have not always been effective at preventing muscle pain or hospitalizations from rhabdomyolysis. Researchers have explored alternative fat sources, including a specialized seven-carbon fat called triheptanoin, which provides an alternate fuel pathway for the mitochondria. In one dietary protocol, patients consumed roughly 37% of calories from carbohydrates, 13% from protein, 20% from regular fat, and the remaining 30% from this specialized fat.
Beyond diet, avoiding known triggers is central to daily management. That means eating regular meals and not skipping them, avoiding prolonged or intense exercise without adequate fueling, staying warm in cold weather, and being especially cautious during illnesses when the body’s energy demands spike. People with the myopathic form can often stay active with moderate exercise, as long as they eat beforehand and don’t push past their limits.
For the severe infantile form, management is more intensive and focuses on preventing the dangerous drops in blood sugar and supporting heart and liver function during crises. Frequent feeding schedules and avoidance of fasting are critical, particularly during illness.